07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

MGCD516: Interim Phase I data

Interim data from 28 patients with advanced solid tumors in the Phase I portion of an open-label, dose-escalation, U.S. Phase I/Ib trial showed that once-daily 10, 20, 40, 80, 110 and 150 mg doses of...
08:00 , Dec 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer AXL receptor tyrosine kinase (AXL; UFO); discoidin domain receptor tyrosine kinase 2 (DDR2); c-Met proto-oncogene (MET;...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

MGCD516: Phase I started

Mirati began an open-label, dose-escalation, U.S. Phase I/Ib trial of oral MGCD516 in about 120 patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). The Phase I portion will...
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Discoidin domain receptor tyrosine kinase 2 (DDR2) In vitro...
07:00 , Apr 11, 2013 |  BC Innovations  |  Cover Story

RET, set, go

Just 15 months after Ret proto-oncogene fusions were first identified in 1%-2% of non-small cell lung cancer cases, early data from a Phase II trial of Exelixis Inc.'s Cometriq cabozantinib suggest that blocking the target...
07:00 , Mar 11, 2013 |  BioCentury  |  Emerging Company Profile

Blackfield: Mining cancer genomes

Blackfield AG is leveraging the genome analysis experience and oncology expertise of its academic founders to offer a one-stop shop for cancer genomics-based drug discovery services. The University of Cologne spinout was founded last year to...
08:00 , Mar 1, 2012 |  BC Innovations  |  Cover Story

REThinking lung cancer

Less than five years after the discovery of the EML4-ALK oncogenic fusion protein as a driver of non-small cell lung cancers, and less than a year after the FDA approved Pfizer Inc.'s Xalkori crizotinib to...
07:00 , May 19, 2011 |  BC Innovations  |  Cover Story

The DDR is in

The clinical success of Pfizer Inc.'s crizotinib anaplastic lymphoma kinase (ALK) inhibitor illustrates that attacking oncogenic drivers can substantially improve outcomes in small groups of non-small cell lung cancerpatients. Now, an international team has identified...
07:00 , May 12, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Discoidin domain receptor tyrosine kinase 2 (DDR2) ...